EA201992103A1 - Получение кристаллического фармацевтического продукта - Google Patents

Получение кристаллического фармацевтического продукта

Info

Publication number
EA201992103A1
EA201992103A1 EA201992103A EA201992103A EA201992103A1 EA 201992103 A1 EA201992103 A1 EA 201992103A1 EA 201992103 A EA201992103 A EA 201992103A EA 201992103 A EA201992103 A EA 201992103A EA 201992103 A1 EA201992103 A1 EA 201992103A1
Authority
EA
Eurasian Patent Office
Prior art keywords
obtaining
pharmaceutical product
crystal pharmaceutical
crystal
particles
Prior art date
Application number
EA201992103A
Other languages
English (en)
Inventor
Мерья Хартева
Анна Стаффанс
Original Assignee
Орион Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61599196&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201992103(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Орион Корпорейшн filed Critical Орион Корпорейшн
Publication of EA201992103A1 publication Critical patent/EA201992103A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к кристаллическим частицам N-((S)-1-(3-(3-хлор-4-цианофенил)-1H-пиразол-1-ил)пропан-2-ил)-5-(1-гидроксиэтил)-1H-пиразол-3-карбоксамида (I), имеющим область удельной поверхности (SSA) в диапазоне от приблизительно 8 до приблизительно 16 м/г, предпочтительно от приблизительно 10 до приблизительно 15 м/г, и к способу получения таких частиц. Соединение (I) является мощным модулятором рецептора андрогена (AR), который может быть использован в качестве лекарственного средства, например, в лечении рака предстательной железы.
EA201992103A 2017-03-07 2018-02-27 Получение кристаллического фармацевтического продукта EA201992103A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20175202 2017-03-07
PCT/FI2018/050143 WO2018162793A1 (en) 2017-03-07 2018-02-27 Manufacture of a crystalline pharmaceutical product

Publications (1)

Publication Number Publication Date
EA201992103A1 true EA201992103A1 (ru) 2020-01-24

Family

ID=61599196

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992103A EA201992103A1 (ru) 2017-03-07 2018-02-27 Получение кристаллического фармацевтического продукта

Country Status (13)

Country Link
US (1) US11168058B2 (ru)
EP (1) EP3592732A1 (ru)
JP (1) JP7157071B2 (ru)
KR (2) KR102676383B1 (ru)
CN (1) CN110382467A (ru)
AU (1) AU2018229817B2 (ru)
BR (1) BR112019018458A2 (ru)
CA (1) CA3055019A1 (ru)
CL (2) CL2019002540A1 (ru)
EA (1) EA201992103A1 (ru)
MX (1) MX2019010452A (ru)
UA (1) UA126071C2 (ru)
WO (1) WO2018162793A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3759076A1 (en) 2018-02-27 2021-01-06 Sandoz AG Crystalline form ii of darolutamide
JP2022539142A (ja) 2019-07-02 2022-09-07 オリオン コーポレーション ダロルタミドの医薬組成物
WO2022036782A1 (zh) * 2020-08-18 2022-02-24 拜耳消费者护理股份有限公司 一种雄激素受体拮抗剂药物的晶型csvi及其制备方法和用途
WO2022144926A1 (en) * 2020-12-31 2022-07-07 Msn Laboratories Private Limited, R&D Center Process for the preparation of amorphous n-{(2s)-1-[3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl]propan-2-yl}-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide
WO2023161458A1 (en) 2022-02-28 2023-08-31 Química Sintética, S.A. Crystalline form of darolutamide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009513622A (ja) * 2005-10-27 2009-04-02 ルピン・リミテッド ロサルタンの医薬製剤
WO2008146590A1 (ja) * 2007-05-28 2008-12-04 Mitsubishi Shoji Foodtech Co., Ltd. 球形マンニトール結晶粒子
CA2755314A1 (en) * 2009-03-12 2010-09-16 Medichem, S.A. New crystals of a benzoylbenzeneacetamide derivative
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
BR112013026905B1 (pt) 2011-04-21 2021-09-14 Orion Corporation Compostos de carboxamida moduladora do receptor de andrógeno e seu uso no tratamento e prevenção de câncer de próstata, bem como composições farmacêuticas compreendendo os ditos compostos
MX2013012771A (es) * 2011-05-04 2013-11-21 Merck Sharp & Dohme Proceso para la preparacion de inhibidores del virus de la hepatitis c.
PT3250554T (pt) * 2015-01-30 2022-06-02 Orion Corp Um derivado de carboxamida e os seus diastereómeros na forma cristalina estável
DK3495352T3 (da) * 2016-08-26 2021-05-03 Crystal Pharmaceutical Suzhou Co Ltd Krystalformer af en androgenreceptorantagonist, fremgangsmåde til fremstilling og anvendelse deraf

Also Published As

Publication number Publication date
CL2023002780A1 (es) 2024-01-26
WO2018162793A1 (en) 2018-09-13
AU2018229817A1 (en) 2019-10-24
US11168058B2 (en) 2021-11-09
JP2020510018A (ja) 2020-04-02
KR102676383B1 (ko) 2024-06-20
CL2019002540A1 (es) 2020-01-31
UA126071C2 (uk) 2022-08-10
BR112019018458A2 (pt) 2020-04-14
AU2018229817B2 (en) 2021-09-30
EP3592732A1 (en) 2020-01-15
US20200039940A1 (en) 2020-02-06
JP7157071B2 (ja) 2022-10-19
KR20240096691A (ko) 2024-06-26
CA3055019A1 (en) 2018-09-13
MX2019010452A (es) 2019-10-15
KR20190126111A (ko) 2019-11-08
CN110382467A (zh) 2019-10-25

Similar Documents

Publication Publication Date Title
EA201992103A1 (ru) Получение кристаллического фармацевтического продукта
PH12020500171A1 (en) 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
CY1121062T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου alzheimer
MX2020006460A (es) Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
PH12017500503A1 (en) Mono- or di-substituted indoles as dengue viral replication inhibitors
EA201691853A1 (ru) Агонисты мускариновых рецепторов
CL2019000397A1 (es) Proceso para preparar el compuesto n-((s)-1-(3-(3-cloro -4-cianofenil)-1h-pirazol-1-il)-5-(1-hidroxi-etil)-1h-pirazol-3-carboxamida de la formula (1a).(divisional solicitud 201702491)
MX2020006459A (es) Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
EA201692007A1 (ru) Соединения изоиндолинона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений
PH12021550324A1 (en) 5 to 7 membered heterocyclic amides as jak inhibitors
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
EA201692008A1 (ru) Замещенные сконденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
EA201791829A1 (ru) Амидные соединения в качестве агонистов рецептора 5-ht
EA202091428A1 (ru) Замещенные амиды ii пирролидина
EA201991898A1 (ru) Двойные ингибиторы magl и faah
NZ720879A (en) Indazole compounds as 5-ht4 receptor agonists
MX2017013101A (es) Piridopirimidinonas y utilizacion de las mismas como moduladores de receptores de n-metil-d-aspartato (nmda).
EA202091429A1 (ru) Замещенные амиды i пирролидина
PH12021550258A1 (en) Cdk8/19 inhibitors
NZ727251A (en) Novel polymorphic form of n-[2-(6-fluoro-1h-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of alzheimer’s
PH12020500393A1 (en) Mpges-1 inhibitor for the treatment of osteoarthritis pain
EA202090602A1 (ru) ИНГИБИТОР mPGES-1 ДЛЯ ЛЕЧЕНИЯ ОСТЕОАРТРИТНОЙ БОЛИ
PH12019502792A1 (en) Tetrahydropyridopyrazine modulators of gpr6